Clinical updates, including trial initiations, enrollment status and data readouts and publications: Biosig, Icad, Immunexpress.

Med-tech firms raising money in public or private financings, including: Ansa Biotechnologies, Hologic, Medigate, Rejoni, Spine Align.

New hires and promotions in the med-tech industry, including: Apiject, Clearpoint Neuro, Element Science, Experity, Microbix, Orthofix, Prolucent, Rapid Micro Biosystems, Satellite Healthcare, Varian.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Ampio, Astrazeneca, Blade, Calliditas, Celltrion, Celularity, Corvus, Cyxone, Daiichi Sankyo, Diffusion, Eli Lilly, Humanigen, Inflarx, Kamada, Octapharma, Pfizer, Pharmabcine, Recce, Regeneron, Sinovac, Seneca, Takeda, Verona.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Aldeyra, Appili, Arch, Ascentage, Beigene, Beyondspring, Canbridge, Gan & Lee, Gannex, Junshi, Kiadis, Mateon, Reven, SK, Vaxart, Zai.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Anges, Anheart, ABL, Arctoris, Ascletis, Asia Green, Astrazeneca, Atomwise, Auris Medical, Axon Neuroscience, Berg, Biocomo, Biontech, Brickell, Caladrius, Canbridge, Cheplapharm Arzneimittel, China SXT, Clinuvel, Cmab, Cymerus, Daiichi Sankyo, Destiny, Exmceuticals, Gain, Galmed, GC Pharma, Gigagen, Ginkgo Bioworks, Glaxosmithkline, Glycot, Harbour Biomed, Hifibio, Hualan Genetic Engineering, Ibio, Icanomab, Immunomic, Inovio, Inveniai, Johnson & Johnson, Know Bio, Laekna Therapeutics Shanghai, Mab Discovery, Medicinova, Medigen, Moderna, Molecular Partners, Moleculin, Monopar, Northstar Medical Radioisotopes, Novavax, Orexo, Otsuka, Pathway Rx, Pfizer, Presage, Prism Biolab, Recce, Redhill, Regenerx, Rockwell Medical, Sanofi, Sporegen, Starpharma, Sumitomo Dainippon, Sun, Syntekabio, Takeda, Totient, Valneva, Vaxart, Vaxess, Vaxil.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Oncoimmune.

New hires and promotions in the biopharma industry in Asia-Pacific, including: Opthea.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aerie, Amryt, Apellis, Ardelyx, Astrazeneca, BMS, Boehringer, Epimab, Equillium, Gensight, Gilead, Kiniksa, Lilly, Mateon, Matinas, Novartis, Plus, Takeda, Zynerba.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adicet, Alimera, Anelixis, Applied Stemcell, Axovant, Bayer, Biontech, BMS, Bostongene, C3.ai, Cell and Gene Therapy Catapult, Cellinta, Combigene, Corino, Cullinan, Cue, ERS Genomics, Exelixis, Fosun, Genexine, Humanigen, Iconic, Innovation Pharma, Kiadis, Mabion, Medis, Melior, Mindset, Miragen, Momenta, Mylan, Novavax, Novus, Obsidian, Oligomerix, Pfizer, Protokinetix, Restorbio, Serum Institute of India, Soligenix, Systems Oncology, Teva, Tonix, Vaxine.